Bismuth-containing drugs in clinical practice in the XXI century - history or a new round of possibilities?
https://doi.org/10.51793/OS.2024.27.9.009
Abstract
Background. Bismuth is a somewhat rare element, similar in content to silver and mercury, but cheaper to produce because large amounts of bismuth are extracted as a by-product of copper and tin processing. Bismuth and its compounds are considered moderately safe and relatively non-toxic. The relatively low toxicity of bismuth compounds is mainly due to their insolubility in nearly neutral aqueous solutions, such as biological fluids. In addition, most bismuth compounds have been demonstrated to be less toxic than even sodium chloride.
Objective. The aim of the article – to outline the feasibility of clinical use of bismuth preparations in the XXI century. Despite many years of using bismuth preparations in clinical practice, the relevance of their use does not weaken, but on the contrary, new niches for its use in clinical practice are opening up. In addition to the well-known cytoprotective effect, the bismuth preparation serves as a worthy alternative to standard triple therapy in the form of quadruple therapy with bismuth preparations, the main one of which is currently bismuth tripotassium dicitrate, which is reflected in the recommendations of the Russian Gastroenterological Association and the Endoscopic Society RENDO. The high efficiency of the possibility of combining bismuth tripotassium dicitrate not only with tetracycline, but also with other antibiotics is shown. The addition of bismuth tripotassium dicitrate to triple regimens containing clarithromycin, levofloxacin, metronidazole allows to increase the effectiveness of eradication by more than 92% with a 14-day course of use. Important bonuses of clinical application of bismuth tripotassium dicitrate are absence of resistance development during its application, combination of bactericidal and cytoprotective effects, as well as good tolerability. Currently, new antibacterial properties of bismuth tripotassium dicitrate are being discovered for treatment of other pathogens, besides Helicobacter pylori. One of worthy representatives of bismuth tripotassium dicitrate is Russian mediication based on bismuth tripotassium dicitrate, which has improved profile of antibacterial activity and safety.
About the Author
V. A. Akhmedov
Omsk State Medical University
Россия
Россия
Vadim A. Akhmedov, Dr. of Sci. (Med.), Professor, Head of the Department of Medical Rehabilitation of Additional Professional Education
5 Petra Nekrasova str., Omsk, 644037
References
1. Silvestru C., Breunig H. J., Althaus H. Structural Chemistry of Bismuth Compounds. I. Organobismuth Derivatives. Chem. Rev. 1999; 99: 3277-3327.
2. Mendis A. H. W., Marshall B. J. Helicobacter pylori and Bismuth In: Biological Chemistry of Arsenic, Antimont and Bismuth. Ed. Sun H. Wiley; 2011. P. 241-262.
3. Shindina T. S., Kropova O. E., Maksimov M. L., et al. The use of bismuth tricalium dicitrate preparations for the treatment of inflammatory diseases of the stomach and duodenum. RMJ. 2017; 10: 703-706. (In Russ.)
4. Yuan X., Yang T., Yao J., et al. Clinical Efficacy of Diet Intervention Combined with Bismuth Potassium Citrate in Helicobacter pylori-Related Chronic Atrophic Gastritis. Altern Ther Health Med. 2023; 29 (8): 846-849.
5. Wang J., Cao Y., He W., Li X. Efficacy and safety of bismuth quadruple regimens containing tetracycline or furazolidone for initial eradication of Helicobacter pylori. Medicine (Baltimore). 2021; 100 (51): e28323. DOI: 10.1097/MD.0000000000028323.
6. Yukhin Yu. M., et al. An anti-ulcer drug based on the substance bismuth (III) potassium dicitrate. Butler's Communications. 2014; 38 (4): 87-93. (In Russ.)
7. Burova L. G., Yukhin Yu. M., et al. Investigation of antibacterial properties of bismuth-containing substances based on nanoparticles. J SIBER MED SCI. 2015; 3: 8. (In Russ.)
8. Wang L., Lin Z., Chen S., et al. Ten-day bismuth-containing quadruple therapy is effective as first-line therapy for Helicobacter pylori-related chronic gastritis: a prospective randomized study in China. J. Clin Microbiol Infect. 2017; 23 (6): 391-395. DOI: 10.1016/j.cmi.2016.12.032.
9. Aumpan N., Mahachai V., Vilaichone R. K. Management of Helicobacter pylori infection. JGH Open. 2022; 7 (1): 3-15. DOI: 10.1002/jgh3.12843.
10. Sun Q., Yuan C., Zhou S., et al. Helicobacter pylori infection: a dynamic process from diagnosis to treatment. Front Cell Infect Microbiol. 2023; 13: 1257817. DOI: 10.3389/fcimb.2023.1257817. eCollection 2023.
11. Niu Z. Y., Li S. Z., Shi Y. Y., Xue Y. Effect of gastric microbiota on quadruple Helicobacter pylori eradication therapy containing bismuth. World J Gastroenterol. 2021; 27 (25): 3913-3924. DOI: 10.3748/wjg.v27.i25.3913.
12. Serena P., Popa A., Bende R., et al. Prevalence of Helicobacter pylori Infection and Efficacy of Bismuth Quadruple and Levofloxacin Triple Eradication Therapies: A Retrospective Analysis. Life (Basel). 2024; 14 (7): 885. DOI: 10.3390/life14070885.
13. Losurdo G., Borraccino A. V.. Aloisio A., et al. Concomitant and Bismuth Quadruple Therapy for Helicobacter pylori Eradication in Southern Italy: Preliminary Data from a Randomized Clinical Trial. Antibiotics. 2024; 13: 348.
14. Nyssen O. P., Bordin D., Tepes B., et al. European Registry on Helicobacter pylori Management (Hp-EuReg): Patterns and Trends in First-Line Empirical Eradication Prescription and Outcomes of 5 Years and 21 533 Patients. Gut. 2021; 70: 40-54.
15. Arslan M., Balamtekin N., Günal A. Efficacy of a novel sequential treatment regimen containing bismuth for Helicobacter pylori eradication in Turkish children. Helicobacter. 2020; 25(6): e12757. DOI: 10.1111/hel.12757.
16. Kiani F., Khademolhosseini S., Mohammadi J., et al. Novel Information Regarding the Treatment of Helicobacter pylori Infection: A Systematic Review and Meta-analysis of Randomized Clinical Trials. Curr Rev Clin Exp Pharmacol. 2024; 19 (2): 184-203. DOI: 10.2174/2772432818666230120111237.
17. Poonyam P., Chotivitayatarakorn P., Vilaichone R. K. High Effective of 14-Day High-Dose PPI- Bismuth-Containing Quadruple Therapy with Probiotics Supplement for Helicobacter Pylori Eradication: A Double Blinded-Randomized Placebo-Controlled Study. Asian Pac J Cancer Prev. 2019; 20 (9): 2859-2864. DOI: 10.31557/APJCP.2019.20.9.2859.
18. Zhou L., Lu H., Song Z., et al. 2022 Chinese national clinical practice guideline on Helicobacter pylori eradication treatment. Chin Med J (Engl). 2022; 135 (24): 2899-2910. DOI: 10.1097/CM9.0000000000002546.
19. Gisbert J. P., Alcedo J., Amador J., et al. V Spanish Consensus Conference on Helicobacter pylori infection treatment. Gastroenterol Hepatol. 2022; 45 (5): 392-417. DOI: 10.1016/j.gastrohep.2021.07.011.
20. Ivashkin V. T., Maev I. V., Lapina T. L., et al. Clinical Recommendations of Russian Gastroenterological Association and RENDO Endoscopic Society on Diagnosis and Treatment of Gastritis and Duodenitis. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2021; 31 (4): 70-99. https://doi.org/10.22416/1382-4376-2021-31-4-70-99. (In Russ.)
21. Burke K. J., Stephens L. E., Werrett M. V., et al. Bismuth(III) Flavonolates: The Impact of Structural Diversity on Antibacterial Activity, Mammalian Cell Viability and Cellular Uptake. Chem. A Eur. J. 2020; 26: 7657-7671.
22. Herdman M. E., Werrett M. V., Andrews P. C. Aryl Bismuth Phosphinates [BiAr2(O(O)PRR′ )]: Structure-Activity Relationships for Antibacterial Activity and Cytotoxicity. Dalton Trans. 2022; 51: 9323-9335.
23. Stephens L. J., Munuganti S., Duffin R. N., et al. Is Bismuth Really the "Green" Metal? Exploring the Antimicrobial Activity and Cytotoxicity of Organobismuth Thiolate Complexes. Inorg. Chem. 2020; 59: 3494-3508.
24. Rostamifar S., Azad A., Bazrafkan A., еt al. New Strategy of Reducing Biofilm Forming Bacteria in Oral Cavity by Bismuth Nanoparticles. BioMed Res. Int. 2021; 2021: 6695692.
25. Bradley B., Singleton M., Po A. L. W. Bismuth Toxicity – A Reassessment. J. Clin. Pharm. Ther. 1989; 14: 423-441.
26. Gonçalves Â., Matias M., Salvador J. A. R., Silvestre S. Bioactive Bismuth Compounds: Is Their Toxicity a Barrier to Therapeutic Use? Int J Mol Sci. 2024; 25 (3): 1600. DOI: 10.3390/ijms25031600.
27. Guiard E., Lelievre B., Rouyer M., et al. Bismuth Concentrations in Patients Treated in Real-Life Practice with a Bismuth Subcitrate-Metronidazole-Tetracycline Preparation: The SAPHARY Study. Drug Saf. 2019; 42: 993-1003.
Review
For citations:
Akhmedov V.A. Bismuth-containing drugs in clinical practice in the XXI century - history or a new round of possibilities? Lechaschi Vrach. 2024;(9):59-63. (In Russ.) https://doi.org/10.51793/OS.2024.27.9.009
Views:
92
JATS XML
Email this article 
